Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06079359 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
A Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT06079359: Active Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
NCT06079359 is a Phase 3 study of Hypophosphatasia that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 30 participants, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06079359, a Phase 3 study of Hypophosphatasia, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN1850
Study Locations (20)
Other
- Research Site - Nedlands
- Research Site - Parkville
- Research Site - Brussels
- Research Site - Brasília
- Research Site - Porto Alegre
- Research Site - Recife
- Research Site - Salvador
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Beijing
- Research Site - Guangzhou
- Research Site - Shanghai
- Research Site - Shenzhen
- Research Site - Helsinki
- Research Site - Ashkelon
Maryland
- Research Site - Baltimore
Missouri
- Research Site - Kansas City
North Carolina
- Research Site - Durham
Alberta
- Research Site - Calgary
Manitoba
- Research Site - Winnepeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2028-08-24 |
| Phase | Phase 3 |
What the registry record for NCT06079359 still lists
NCT06079359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 79-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06079359 names 20 study sites across 6 states, led by Other, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT06079359 about?
NCT06079359 is a clinical study titled "Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP". The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.
What is the current status of trial NCT06079359?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2024-05-14. Estimated completion is 2028-08-24.
What conditions does trial NCT06079359 study?
This clinical trial studies the following conditions: Hypophosphatasia.
What interventions are being tested in trial NCT06079359?
The interventions under investigation include: Placebo (DRUG), ALXN1850 (DRUG).
Who is sponsoring clinical trial NCT06079359?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06079359 being conducted?
This trial has 20 study locations across Maryland, Missouri, North Carolina, Alberta, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
United States Hypophosphatasia Molecular Research Center
RECRUITING
-
Natural History Study of Patients With Hypophosphatasia (HPP)
RECRUITING
-
A Prospective Sub-Study of the Global Hypophosphatasia Registry
RECRUITING
-
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI